免疫检查点相关信号通路

机体健康的免疫系统需要一系列检查点,以维持自体耐受或防止在免疫反应中其他组织受到损坏。CD8+ 细胞毒T细胞或 CD4+ 辅助T细胞的激活因T细胞受体 (TCR) 与抗原呈递细胞(APC)表面上处于结合主要组织相容性复合体 (MHC) 分子的肽抗原形式的抗原相互作用而发生 。此外,T 细胞上共刺激信号转导分子(例如 CD28、ICOS(CD278)、GITR(CD357)与 APC 上其受体(例如,CD80(B7-1)/CD86(B7-2)、ICOSL、GITRL)的结合还可能有助于 T 细胞激活[1]。然而,在某些情况下,T细胞受体参与过程伴有抑制T细胞活化和反应的抑制性信号。这些信号由涉及免疫检查点抑制的蛋白质如 PD-1(B7-H1;CD274)、CTLA-4(CD152)、TIM-3(CD366)和 LAG3(CD223)生成[2-5]。在正常条件下,这些蛋白对于机体自我耐受至关重要。但在肿瘤中,这些免疫检查点蛋白可以允许肿瘤逃避抗肿瘤免疫应答[6-8]。如PD-1 和 CTLA-4 免疫检查点蛋白通常在浸润肿瘤的T细胞中上调,结合其相应的配体,分别是 PD-L1/PD-L2(B7-DC;CD273)及CD80/86,并且下调T细胞反应。因此,通过阻断免疫检查点蛋白激活抗肿瘤免疫已成为癌症治疗(如:抗PD-1免疫疗法)的热点研究和药物开发重点项目[9]。通过对免疫检查点进行特异性的干预(阻断“共抑制分子(co-stimulatory)”或者提高“共刺激分子(co-inhibitory)”),从而实现免疫系统的“再平衡”而使免疫系统发挥有效的抗肿瘤反应,这种新的癌症治疗方法被称为肿瘤的免疫疗法,并且极大地改变了肿瘤的治疗策略。
除了这些胞膜表面分子,细胞内的代谢途径在免疫细胞调节中也发挥重要作用,并被延伸作为免疫检查点来对待。例如,在肿瘤细胞和髓系细胞中, indoleamine 2, 3-dioxygenase (IDO) 和arginase作为关键酶,通过改变氨基酸代谢过程造成T细胞效应功能的抑制[10]。

ABclonal针对免疫检查点相关信号通路研究,提供以下常见核心靶点的产品

PD-L1/CD274 Rabbit mAb

ABflo® 488 Rabbit anti-Human CD86 mAb

ABflo® 488 Rabbit anti-Human PD-L1/CD274 mAb

ABflo® 488 Rabbit anti-Human CD27 mAb

ABflo® 488 Rabbit anti-Human CD28 mAb

PE Rabbit anti-Human CD152/CTLA-4 mAb

ABflo® 594 Rabbit anti-Human CD47 mAb

ABflo® 594 Rabbit anti-Mouse CD47 mAb

免疫检查点相关信号通路精选研究产品

分类
研究靶点 产品名称 产品货号
Co-stimulatory Molecules
CD27CD27 Rabbit mAbA11505
CD27ABflo® 488 Rabbit anti-Human CD27 mAbA22063
CD27ABflo® 647 Rabbit anti-Human CD27 mAbA22064
CD28CD28 Rabbit mAbA20346
CD28ABflo® 488 Rabbit anti-Human CD28 mAbA23405
CD28ABflo® 647 Rabbit anti-Human CD28 mAbA23406
Cd28ABflo® 594 Rabbit anti-Mouse CD28 mAbA25058
Cd28ABflo® 488 Rabbit anti-Mouse CD28 mAbA25056
Cd28ABflo® 647 Rabbit anti-Mouse CD28 mAbA25057
CD40ABflo® 488 Rabbit anti-Human CD40 mAbA21938
CD40ABflo® 647 Rabbit anti-Human CD40 mAbA21947
CD70CD70 Rabbit mAbA20589
CD70CD70 Rabbit mAbA22168
CD70ABflo® 488 Rabbit anti-Human CD70 mAbA22302
CD70ABflo® 647 Rabbit anti-Human CD70 mAbA22303
CD86CD86 Rabbit mAbA21198
CD86ABflo® 488 Rabbit anti-Human CD86 mAbA21940
CD86ABflo® 647 Rabbit anti-Human CD86 mAbA21941
ICOSICOS/CD278 Rabbit mAbA5130
Icos/CD278ABflo® 488 Rabbit anti-Mouse ICOS/CD278 mAbA23813
Icos/CD278ABflo® 594 Rabbit anti-Mouse ICOS/CD278 mAbA23815
Icos/CD278ABflo® 647 Rabbit anti-Mouse ICOS/CD278 mAbA23814
MICAMICA Rabbit mAbA19256
TNFRSF94-1BB/CD137 Rabbit mAbA22167
TNFSF94-1BBL/CD137L Rabbit mAbA3386
PVRCD155/PVR Rabbit mAbA23084
Co-inhibitory Molecules
CD274PD-L1/CD274 Rabbit mAbA20270
CD274PD-L1/CD274 Rabbit mAbA19135
CD274ABflo® 488 Rabbit anti-Human PD-L1/CD274 mAbA22304
CD274ABflo® 647 Rabbit anti-Human PD-L1/CD274 mAbA22305
CTLA4CD152/CTLA-4 Rabbit mAbA22865
CTLA4PE Rabbit anti-Human CD152/CTLA-4 mAbA23713
CD276ABflo® 488 Rabbit anti-Human/Mouse CD276/B7-H3 mAbA22156
CD276ABflo® 647 Rabbit anti-Human/Mouse CD276/B7-H3 mAbA22157
HAVCR2ABflo® 488 Rabbit anti-Human TIM-3/HAVCR2 mAbA22158
CD33CD33 Rabbit mAbA22704
CD33ABflo® 488 Rabbit anti-Human CD33 mAbA22639
CD33ABflo® 647 Rabbit anti-Human CD33 mAbA22640
CD47CD47 Rabbit mAbA21904
CD47ABflo® 488 Rabbit anti-Human CD47 mAbA24300
CD47ABflo® 594 Rabbit anti-Human CD47 mAbA24302
CD47ABflo® 647 Rabbit anti-Human CD47 mAbA24301
Cd47ABflo® 488 Rabbit anti-Mouse CD47 mAbA24377
Cd47ABflo® 594 Rabbit anti-Mouse CD47 mAbA24379
Cd47ABflo® 647 Rabbit anti-Mouse CD47 mAbA24378
CD48CD48 Rabbit mAbA4084
CD48ABflo® 488 Rabbit anti-Human CD48 mAbA21937
CD48ABflo® 647 Rabbit anti-Human CD48 mAbA21946
CEACAM1ABflo® 488 Rabbit anti-Human CD66a/CEACAM1 mAbA24383
CEACAM1ABflo® 594 Rabbit anti-Human CD66a/CEACAM1 mAbA24385
CEACAM1ABflo® 647 Rabbit anti-Human CD66a/CEACAM1 mAbA24384
  • 缩略语注释:
  • IDO, indoleamine 2, 3-dioxygenase
  • ICOS, Inducible T-cell costimulator
  • MICA, MHC class I polypeptide-related
  • TIM-3, T-cell immunoglobulin mucin receptor 3
  • CTLA4, Cytotoxic T-lymphocyte protein 4
  • 4-1BB, 4-1BB ligand receptor
  • 4-1BBL, 4-1BB ligand
  • CEACAM1, Carcinoembryonic antigen-related cell adhesion molecule 1
  • PVR, Poliovirus receptor
  • SIGLEC3, Sialic acid-binding Ig-like lectin 3
  • SLAMF2, SLAM family member 2
  • 参考文献:
  • 1.Nature Immunology (2014) 15:790–797
  • 2.Nature reviews immunology (2013) 13: 227–242
  • 3.Nature volume (2021) 595:101–106
  • 4.Nature Immunology (2022) 23:1297–1299
  • 5.N Engl J Med (2023) 389:866-868
  • 6.Nature reviews Cancer  (2012) 12:252–264.
  • 7.Immunity (2016) 44:955–972.
  • 8.Immunity (2015) 44:989–1004.
  • 9.Cell (2016) 161:205–214.
  • 10.Oncoimmunology (2015) 4:e954829